Original Publication Date: 1 August, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Yangqiu Li, Future Science Group
The reversion of immune suppression and restoration of T-cell function against leukemia remains a significant clinical challenge. However, the advent of improved antileukemia-specific T-cell induction and the generation of gene-modified T cells has extended cellular immunotherapy to hematological malignancies.